Patents by Inventor Beatrice Le Bourdelles

Beatrice Le Bourdelles has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7157249
    Abstract: The present invention relates to the cloning of novel cDNA sequences encoding the ?4 and ? receptor subunits of the human GABA A receptor; to stably co-transfected eukaryotic cell lines capable of expressing a human GABAA receptor, which receptor comprises at least one of the novel ?4 and ? receptor subunits; and to the use of such cell lines in screening for and designing medicaments which act upon the human GAGAA receptor.
    Type: Grant
    Filed: August 2, 2002
    Date of Patent: January 2, 2007
    Assignee: Merck Sharp & Dohme Ltd.
    Inventors: Beatrice Le Bourdelles, Paul John Whiting
  • Publication number: 20030013158
    Abstract: The present invention relates to the cloning of novel cDNA sequences encoding the &agr;4 and &dgr; receptor subunits of the human GABAA receptor; to stably co-transfected eukaryotic cell lines capable of expressing a human GABAA receptor, which receptor comprises at least one of the novel &agr;4 and &dgr; receptor subunits; and to the use of such cell lines in screening for and designing medicaments which act upon the human GAGAA receptor.
    Type: Application
    Filed: August 2, 2002
    Publication date: January 16, 2003
    Applicant: Merck Sharp & Dohme, Ltd.
    Inventors: Beatrice Le Bourdelles, Paul John Whiting
  • Patent number: 6455276
    Abstract: The present invention provides nucleotide sequences encoding the &agr;4 and &dgr; subunits of the human GABAA receptor, preparations of &agr;4 and &dgr; receptor subunit proteins, preparations of receptors including &agr;4 or &dgr; polypeptides, expression vectors including the nucleotide sequences, stably co-transfected eukaryotic cells and methods of their preparation and methods of screening for and designing medicaments which act upon the GABAA receptor.
    Type: Grant
    Filed: June 19, 1997
    Date of Patent: September 24, 2002
    Assignee: Merck Sharp & Dohme Ltd.
    Inventors: Beatrice Le Bourdelles, Paul John Whiting
  • Patent number: 6130058
    Abstract: The present invention relates to a stably co-transfected eukaryotic cell line that expresses an N-methyl-D-aspartate (NMDA) receptor, particularly a human NMDA receptor, which receptor comprises at least one R1 subunit isoform, or at least one R1 subunit isoform and one or two R2 subunits. Additionally, the cell line can be used to design and develop NMDA receptor subtype-selective compounds. The invention also relates to cloning of novel cDNA sequences encoding the human NMDAR 2A subunit and various isoforms of the human NMDA R1 subunit.
    Type: Grant
    Filed: May 10, 1995
    Date of Patent: October 10, 2000
    Assignee: Merck Sharpe & Dohme Ltd.
    Inventors: Beatrice Le Bourdelles, Janice Ann Myers, Paul John Whiting
  • Patent number: 5719057
    Abstract: The present invention relates to a stably co-transfected eukaryotic cell line capable of expressing a GABA-A receptor, particularly a human GABA-A receptor, which receptor comprises at least one alpha, one beta and one gamma subunit; to the cloning of novel cDNA sequences encoding the .alpha.-2, .alpha.-3, .alpha.-5, .alpha.-6 and .beta.-2 subunits of the human GABA-A receptor; and to the use of the cell line in designing and developing GABA-A receptor subtype-selective medicaments.
    Type: Grant
    Filed: April 5, 1995
    Date of Patent: February 17, 1998
    Assignee: Merck Sharpe & Dohme Ltd.
    Inventors: Karen Louise Hadingham, Beatrice le Bourdelles, Paul John Whiting, Peter Baxter Wingrove